Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | PLX8394 in patients with advanced cancer: activity, safety and ctDNA

Filip Janku • 19 Sep 2020
ESMO 2020
General Melanoma

Filip Janku, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the activity, safety and circulating tumor DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer. Dynamic changes in plasma ctDNA using droplet digital PCR (ddPCR) and targeted next-generation sequencing (NGS) were compared to treatment outcomes and were predictive of clinical responses in patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Filip Janku

5:12
First-in-human trial of an EGFR/TGFβ fusion protein for advanced solid tumors
Filip Janku • 19 May 2021
7:15
Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer
Filip Janku • 19 May 2021
2:29
Developmental therapeutics updates to look at for at ASCO 2021
Filip Janku • 19 May 2021
8:12
First-in-human trial of intratumoral injection of SYNB1891
Filip Janku • 10 Apr 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals